Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations

2017 Fiscal Year Final Research Report

• Project/Area Number: 26430163
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Okayama University
• Principal Investigator: Hotta Katsuyuki 岡山大学, 大学病院, 教授 (70379816)
• Co-Investigator(Kenkyū-buntansha): 木浦 勝行 岡山大学, 大学病院, 教授 (10243502)
• Research Collaborator: Kato Yuka 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学 ; Tamura Tomoki 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学 ; Ninomiya Kiichiro 岡山大学, 大学院 病態制御科学 血液・腫瘍・呼吸器内科学 ; Ohashi Kadoaki 岡山大学病院, 呼吸器・アレルギー内科
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 肺癌

Outline of Final Research Achievements

In our study, in 52 patients with EGFR-mutat lung cancer who received gefitinib, EGFR tyrosine kinase inhibitor (TKI), the high IL-6 expression group, accouting for 46%, tended to have poor progression-free survival as compared with the low expression group. In pre-clinical studies using cell lines, the efficacy of EGFR tyrosine kinase inhibitor was related to IL-6 expression level. Thus, EGFR-TKI treatment alone seems insufficient in the high IL-6 expression group, and further treatment strategy should be developed.

Free Research Field

臨床腫瘍学